Myocarditis: Current trends in diagnosis and treatment

Circulation

Volumn 113, Issue 6, 2006, Pages 876-890

  Magnani, Jared W ^a,b   Dec, G William ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Heart failure; Myocarditis; Viruses

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIEPILEPSIRINE; AZATHIOPRINE; BETA INTERFERON; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLOZAPINE; COCAINE; CYCLOSPORIN; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; GADOLINIUM; GLYCERYL TRINITRATE; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INOTROPIC AGENT; INTERLEUKIN 2; NEUROLEPTIC AGENT; NITROPRUSSIDE SODIUM; PENICILLIN DERIVATIVE; PREDNISONE; SULFONAMIDE; THYMUS HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; VASODILATOR AGENT;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; COXSACKIE VIRUS B; DYSPNEA; ENTEROVIRUS; FEVER; HEART MUSCLE BIOPSY; HEART PALPITATION; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; INFLAMMATION; MAGNETIC RESONANCE ANGIOGRAPHY; MYALGIA; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUDDEN DEATH; SYMPTOM; VIRUS MYOCARDITIS; CLASSIFICATION; PRACTICE GUIDELINE; VIRUS INFECTION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDITIS; PRACTICE GUIDELINES; VIRUS DISEASES;

EID: 33644850082     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.584532     Document Type: Review

References (119)

1. Fabre A, Sheppard MN. Sudden adult death syndrome and other non ischaemic causes of sudden cardiac death: a UK experience. Heart. 2005 [Epub ahead of print].
2. Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust. 2004;180:110-112.
3. Felker GM, Hu W, Hare JM, Hruban RH, Baughman KL, Kasper EK. The spectrum of dilated cardiomyopathy: the Johns Hopkins experience with 1,278 patients. Medicine (Baltimore). 1999;78:270-283.
4. Grogan M, Redfield MM, Bailey KR, Reeder GS, Gersh RJ, Edwards WD, Rodeheffer RJ. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;26:80-84.
5. McCarthy RE, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute (non-fulminant) myocarditis. N Engl J Med. 2000;342:690-695.
6. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE, for the Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269-275.
7. Dec GW, Palacios IF, Fallon JT, Aretz HT, Mills J, Lee DC, Johnson RA. Active myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates, and clinical outcome. N Engl J Med. 1985;312:885-890.
8. Heart Failure Society of America. HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction: pharmacological approaches. Congest Heart Fail. 2000;6:11-39.
9. Dec GW, Waldman H, Southern J, Fallon JT, Hutter AM, Palacios I. Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol. 1992;20:85-89.
10. Aretz HT, Billingham ME, Edwards WD, Parker MM, Factor SM, Fallon JT, Fenoglio JJ. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1:3-14.
11. Magnani JW, Suk-Danik HJ, Dec GW, DiSalvo TG. Survival in biopsyproven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J. In press.
12. Hauck AJ, Keamey DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc. 1989;64:1235-1245.
13. Shanes JG, Ghali J, Billingham ME, Ferrans VJ, Fenoglio JJ, Edwards WD, Tsai CC, Saffitz JE, Isner J, Forner S. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results. Circulation. 1987;75:401-405.
14. Parrillo JE. Inflammatory cardiomyopathy (myocarditis): which patients should be treated with anti-inflammatory therapy? Circulation. 2001;104:4-6.
15. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL. Clinicopathologic description of myocarditis. J Am Coll Cardiol. 1991;18:1617-1626.
16. Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart. 1997;78:539-543.
17. Wojnicz R, Nowalany-Kozielska E, Wodniecki J, Szczurek-Katanski S, Nozynski J, Zembala M, Rozek MM. Immunohistological diagnosis of myocarditis: potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. Eur Heart J. 1998;19:1564-1572.
18. Griffiths PD, Hannington G, Booth JC. Coxsackie B virus infections and myocardial infarction: results from a prospective, epidemiologically controlled study. Lancet. 1980;1:1387-1389.
19. Keeling PJ, Poloniecki LA, Caforio AL, Davies MJ, Booth JC, McKenna WJ. A prospective case-control study of antibodies to Cox-sackie B virus in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;23:593-598.
20. Grumbach IM, Heim A, Pring-Akerblom P, Vonhof S, Hein WJ, Muller G, Figulla HR. Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy. Acta Cardiol. 1999;54:83-88.
21. Archard LC, Khan MA, Soteriou BA, Zhang H, Why HJ, Robinson NM, Richardson PJ. Characterization of Coxsackie B virus RNA in myocardium from patients with dilated cardiomyopathy by nucleotide sequencing of reverse transcription-nested polymerase chain reaction products. Hum Pathol. 1998;29:578-584.
22. Why HJ, Meany BT, Richardson PJ, Olsen EG, Bowles NE, Cunningham L, Freeke CA, Archard LC. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 1994;89:2582-2589.
23. Pauschinger M, Bowles NE, Fuentes-Garcia FJ, Pham V, Kuhl U, Schwimmbeck PL, Schultheiss HP, Towbin JA. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation. 1999;99:1348-1354.
24. Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, Hare J, Bricker JT, Bowles KR, Towbin JA. Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol. 2003;42:466-472.
25. Sato Y, Yamada T, Matsumori A. Hepatitis C virus and cardiomyopathy. In: Matsumori A, ed. Cardiomyopathies and Heart Failure: Biomolecular, Infectious, and Immune Mechanisms. Boston, Mass: Kluwer Academic Publishers; 2003:325-339.
26. Panhoweit S, Lamparter S, Schoppet M, Maisch B. Parvovirus B19 genome in endomyocardial biopsy specimens. Circulation. 2004;109:e179.
27. Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheisss HP. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation. 2005;111:887-893.
28. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation. 1995;92:2519-2525.
29. Calabrese F, Carturan E, Chimenti C, Pieroni M, Agostini C, Angelini A, Crosato M, Valente M, Boffa GM, Frustaci M, Thiene G. Overexpression of tumor necrosis factor (TNF)alpha and TNFalpha receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol. 2004;17:1108-1118.
30. Hofman P, Drici MD, Gibelin P, Michiels JF, Thyss A. Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome. Br Heart J. 1993;70:376-381.
31. Herskowitz A, Wu TC, Willoughby SB, Vlahov D, Ansari AA, Beschorner WE, Baughman KL. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol. 1994;24:1025-1032.
32. Pulerwitz TC, Cappola TP, Felker GM, Hare JM, Baughman KL, Kasper EK. Mortality in primary and secondary myocarditis. Am Heart J. 2004;147:746-750.
33. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G, for the Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N Engl J Med. 1998;339:1093-1099.
34. Eckart RE, Love SS, Atwood JE, Arness MK, Cassimatis DC, Campbell CL, Boyd SY, Murphy JG, Swerdlow PL, Collins LC, Riddle JR, Tomberg DN, Grabenstein JD, Engler RJ. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol. 2004;44:201-205.
35. Halsell JS, Riddle JR, Atwood JE, Gardner P, Shope R, Poland GA, Gray GC, Ostroff S, Eckart RE, Hospenthal DR, Gibson RL, Grabenstein JD, Arness MK, Tomberg DN. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA. 2003;289:3283-3289.
36. Murphy JG, Wright RS, Bruce GK, Baddour LM, Farrell MA, Edwards WD, Kita H, Cooper LT. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet. 2003;362:1378-1380.
37. Ansari A, Maron BJ, Berntson DG. Drug-induced toxic myocarditis. Tex Heart Inst J. 2003;30:76-79.
38. Burke AP, Saenger J, Mullick F, Virmani R. Hypersensitivity myocarditis. Arch Pathol Lab Med. 1991;115:764-769.
39. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:1841-1845.
40. Frustaci A, Cuoco L, Chimenti C, Pieroni M, Fioravanti G, Gentiloni N, Maseri A, Gasbarrini G. Celiac disease associated with autoimmune myocarditis. Circulation. 2002;105:2611-2618.
41. Southern JF, Moscicki RA, Magro C, Dickersin GR, Fallon JT, Bloch KJ. Lymphedema, lymphocytic myocarditis, and sarcoidlike granulomatosis: manifestations of Whipple's disease. JAMA. 1989;261:1467-1470.
42. Frustaci A, Gentiloni N, Caldarulo M. Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus. Chest. 1996;109:282-284.
43. Whitlow PL, Gilliam JN, Chubick A, Ziff M. Myocarditis in mixed connective tissue disease: association of myocarditis with antibody to nuclear ribonucleoprotein. Arthritis Rheum. 1980;23:808-815.
44. Clemson BS, Miller WR, Luck JC, Feriss JA. Acute myocarditis in fulminant systemic sclerosis. Chest. 1992;101:872-874.
45. Webb JG, Butany J, Langer G, Scott G, Liu PP. Myocarditis and myocardial hemorrhage associated with thrombotic thrombocytopenic purpura. Arch Intern Med. 1990;150:1535-1537.
46. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation. 2001;104:1076-1082.
47. Huber SA. Animal models: immunological aspects. In: Banatvla JE, ed. Viral Infections in the Heart. London, UK: Edward Arnold; 1993:82-109.
48. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091-1100.
49. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.
50. Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000;343:1388-1398.
51. Zaragoza C, Ocampo C, Saura M, Leppo M, Wei XG, Quick R, Moncada S, Liew FY, Lowenstein CJ. The role of inducible nitric oxide synthase in the host response to coxsackievirus myocarditis. Proc Natl Acad Sci U S A. 1998;95:2469-2474.
52. Zaragoza C, Ocampo CJ, Saura M, McMillan A, Lowenstein CJ. Nitric oxide inhibition of Coxsackie replication in vivo. J Clin Invest. 1997;100:1760-1767.
53. Padalko E, Ohnishi T, Matsushita K, Sun H, Fox-Talbot K, Bao C, Baldwin WM, Lowenstein CJ. Peroxynitrite inhibition of coxsackievirus infection by prevention of viral RNA entry. Proc Natl Acad Sci U S A. 2004;101:11731-11736.
54. Mikami S, Kawashima S, Kanazawa K, Hirata K, Hotta H, Kayashi Y, Itoh H, Yokoyama M. Low-dose N omega-nitro-L-arginine methyl ester treatment improves survival rate and decreases myocardial injury in a murine model of viral myocarditis induced by Coxsackievirus B3. Circ Res. 1997;81:504-511.
55. Seko Y, Tsuchimochi H, Nakamura T, Okumara K, Naito S, Imataka K, Fujii J, Takaku F, Yazaki Y. Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with Coxsackievirus B3. Circ Res. 1990:67:360-367.
56. Pankuweit S, Portig I, Lottspeich F, Maisch B. Autoantibodies in sera of patients with myocarditis: characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis. J Mol Cell Cardiol. 1997;29:77-84.
57. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR. Contributions of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol. 2001;2:739-745.
58. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S, Neumayer HH, Wemecke KD, Wallukat G, Stangl K, Bauman G. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000;35:1590-1598.
59. Felix SB, Staudt A, Landsberger M, Crosse Y, Stangl V, Spielhagen T, Wallakut G, Wemecke KD, Bauman G, Stangl K. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol. 2002;39:646-652.
60. Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K, Wallakut G, Wemecke KD, Stangl K, Baumann G, Felix SB. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and immunoglobulin substitution. Circulation. 2001;103:2681-2686.
61. Opavsky MA, Penninger J, Aitken K, Wen WH, Dawood F, Mak T, Liu P. Susceptibility to myocarditis is dependent on the response of T lymphocytes to coxsackieviral infection. Circ Res. 1999;85:551-558.
62. d'Amati G, di Gioia CR, Gallo P. Pathological findings of HIV-associated cardiovascular disease. Ann N Y Acad Sci. 2001;946:23-45.
63. Cooper LT. Giant cell myocarditis: diagnosis and treatment. Herz. 2000;25:291-298.
64. Theaker JM, Gatter KC, Heryet A, Evans DJ, McGee JO. Giant cell myocarditis: evidence for the macrophage origin of the giant cells. J Clin Pathol. 1985;38:160-164.
65. Kim KS, Tracey S, Tapprich W, Bailey J, Lee CK, Kim K, Barry WH, Chapman NM. 5′-Terminal deletions occur in Coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. J Virol. 2005;79:7024-7041.
66. Okabe M, Fukuda K, Arakawa K, Kikuchi M. Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation. 1997;96:22-24.
67. Dec GW. Introduction to clinical myocarditis. In: Cooper LT, ed. Myocarditis: From Bench to Bedside. Totowa, NJ: Humana Press; 2003:257-281.
68. Felker GM, Thompson RE, Hare JM, Hruban RH, Clementson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-1084.
69. Herskowitz A, Campbell S, Deckers J, Kasper EK, Boehmer J, Hadian D, Neumann DA, Baughman KL. Demographic features and prevalence of idiopathic myocarditis in patients undergoing endomyocardial biopsy. Am J Cardiol. 1993;71:982-986.
70. Cooper LT, Berry GJ, Shabetai R, for the Multicenter Giant Cell Myocarditis Study Group Investigators. Idiopathic giant-cell myocarditis: natural history and treatment. N Engl J Med. 1997;336:1860-1866.
71. Angelini A, Calzolari V, Calabrese F, Boffa GM, Maddalena F, Chioin R, Thiene G. Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis. Heart. 2000;84:245-250.
72. Sarda L, Colin P, Boccara F, Daou D, Lebtahi R, Faraggi M, Nguyen C, Cohen A, Salma MS, Steg PG, LeGuludec D. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol. 2001;37:786-792.
73. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis: experimental and clinical correlates. Circulation. 1997;95:163-168.
74. Okura Y, Dec GW, Hare JM, Kodama M, Berry GJ, Tazelaar HD, Bailey KR, Cooper LT. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003;41:322-325.
75. Drory Y, Turetz Y, Hiss Y, Lev B, Fishman EZ, Pines A, Kramer MR. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol. 1991;68:1388-1392.
76. Murphy JG, Franz RP. Endomyocardial biopsy in myocarditis. In: Cooper LT, ed. Myocarditis: From Bench to Bedside. Totowa, NJ: Humana Press; 2003.
77. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2005;112:1825-1852.
78. Wu LA, Lapeyre AC III, Cooper LT. Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis. Mayo Clin Proc. 2001;76:1030-1038.
79. Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997;30:1354-1359.
80. Greaves K, Oxford JS, Price CP, Clarke GH, Crake T. The prevalence of myocarditis and skeletal muscle injury during acute viral infection in adults: measurement of cardiac troponins I and T in 152 patients with acute influenza infection. Arch Intern Med. 2003;163:165-168.
81. Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Saffredini AF, Brenner M, Schear GL, Palmeri ST, Cannon RO, Alling D. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321:1061-0168.
82. Huber S. Cellular autoimmunity in myocarditis. Heart Fail Clin. 2005;1:321-331.
83. Neumann DA, Burek CL, Baughman KL, Rose NR, Herskowitz A. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol. 1990;16:839-846.
84. Cassling RS, Linder J, Sears TD, Waller BF, Rogler WC, Wilson JE, Kugler JD, Kay DH, Dillon JC, Slack JD, McManus BM. Quantitative evaluation of inflammation in biopsy specimens from idiopathically failing or irritable hearts: experience in 80 pediatric and adult patients. Am Heart J. 1985;110:713-720.
85. Kuhl U, Seeberg B, Schultheiss HP, Strauer BE. Immunohistological characterization of infiltrating lymphocytes in biopsies of patients with clinically suspected dilated cardiomyopathy. Eur Heart J. 1994;15(suppl C):62-67.
86. Herskowitz A, Ahmed-Ansari A, Neumann DA, Beschorner WE, Rose NR, Soule LM, Burek CL, Sell KW, Baughman KL. Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. J Am Coll Cardiol. 1990;15:624-632.
87. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T, Zembala M, Polonski L, Wodniecki J, Rozek MM. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39-45.
88. Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F, Camerini F. Echocardiographic findings in myocarditis. Am J Cardiol. 1988;62:285-291.
89. Piamonti B. Contribution of echocardiography to the diagnosis of patients with chronic heart failure. Ital Heart J. 2000;1(suppl):1311-1316.
90. Adsett M, West MJ, Galbraith A, Duhig E, Lange A, Palka P. Eosinophilic heart: marked left ventricular wall thickening and myocardial dysfunction improving on corticosteroid therapy. Echocardiography. 2003;20:369-374.
91. Lieback E, Hardouin I, Meyer R, Bellach J, Hetzer R. Clinical value of echocardiographic tissue characterization in the diagnosis of myocarditis. Eur Heart J. 1996;17:135-142.
92. Dec GW, Palacios I, Yasuda T, Fallon JT, Khaw BA, Strauss HW, Haber E. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol. 1990;16:97-104.
93. Margari ZJ, Anastasiou-Nana MI, Terrovitis J, Toumanidis S, Agapitos EV, Lekakis JP, Nanas JN. Indium-111 monoclonal antimyosin cardiac scintigraphy in suspected active myocarditis: evolution and diagnostic impact. Int J Cardiol. 2003;90:239-245.
94. Laissy JP, Messin B, Varenne O, Iuag B, Karila-Cohen D, Schouman-Claeys E, Steg PG. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest. 2002;122:1638-1648.
95. Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 1998;97:1802-1809.
96. Roditi GH, Hartnell GG, Cohen MC. MRI changes in myocarditis: evaluation with spin echo, cine MR angiography and contrast enhanced spin echo imaging. Clin Radiol. 2000;55:752-758.
97. Smedama JP, Snoep G, van Kroonenburgh MP, van Guens RJ, Dassen WR, Gorgels AP, Crijns HJ. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-1690.
98. Abdel-Ary H, Boye P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, Bock P, Dietz R, Friedrich MG, Schulz-Menger J. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45:1812-1822.
99. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, Firtz P, Klingel K, Kandolf R, Sechtem U. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250-1258.
100. Eckart RE, Shry EA, Jones SO, Atwood JE, Grabenstein JD. Comparison of clinical presentation of acute myocarditis following smallpox vaccination to acute coronary syndromes in patients <40 years of age. Am J Cardiol. 2005;95:1252-1255.
101. Kato S, Morimoto S, Hiramitsu S, Nomura M, Ito T, Hishida H. Use of percutaneous cardiopulmonary support of patients with fulminant myocarditis and cardiogenic shock for improving prognosis. Am J Cardiol. 1999;83:623-625.
102. Fuse K, Kodama M, Okura Y, Itu M, Hirono S, Kato K, Hanana H, Aizawa Y. Predictors of disease course in patients with acute myocarditis. Circulation. 2000;102:2829-2835.
103. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: Patients with myocarditis are at higher risk. Circulation. 2002;105:1663-1668.
104. Dec GW, Fallon JT, Southern JF, Palacios IF. Relation between histological findings on early repeat right ventricular biopsy and ventricular function in patients with myocarditis. Br Heart J. 1988;60:332-337.
105. Figulla HR, Stille-Siegener M, Mall G, Heim A, Kreuzer H. Myocardial enterovirus infection with left ventricular dysfunction: a benign disease compared with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1995;25:1170-1175.
106. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107:857-863.
107. Cooper LT, Okura Y, Hare JM, Grogan M. Survival in biopsy-proven cardiac sarcoidosis is similar to survival in lymphocytic myocarditis and dilated cardiomyopathy. In: Kimchi A, ed. Heart Disease: New Trends in Research, Diagnosis, and Treatment. Englewood, NJ: Medimond Medical Publications; 2001:491-496.
108. Farrar DJ, Holman WR, McBride LR, Kormos RL, Icenogle TB, Hendry PJ, Moore CH, Loisance DY, El-Banayosy A, Fraiser H. Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transplant. 2002;21:516-521.
109. Hobbs RE, Pelegrin D, Ratliff NB, Bott-Silverman C, Rincon G, Sterba R, Badhwar K. Lymphocytic myocarditis and dilated cardiomyopathy: treatment with immunosuppressive agents. Cleve Clin J Med. 1989;56:628-635.
110. Salvi A, Di Lenarda A, Dreas L, Silvestri F, Camerini F. Immunosuppressive treatment in myocarditis. Int J Cardiol. 1989;22:329-338.
111. Menghini VV, Savcenko V, Olson LJ, Tazelaar HD, Dec GW, Kao A, Cooper LT. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc. 1999;74:1221-1226.
112. Tedeschi A, Airaghi L, Giannini S, Ciceri L, Massari FM. High-dose intravenous immunoglobulin in the treatment of acute myocarditis: a case report and review of the literature. J Intern Med. 2002;251:169-173.
113. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254-2259.
114. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220-225.
115. Noutsias M, Seeberg B, Schultheiss HP, Kuhl U. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation. 1999;99:2124-2131.
116. Mason JW. Immunopathogenesis and treatment of myocarditis: the United States myocarditis treatment trial. J Card Fail. 1996;2:S173-S177.
117. Daliento L, Calabrese F, Tona F, Caforio AL, Tarsia G, Angelini A, Thiene G. Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant. 2003;22:214-217.
118. Miric M, Vasiljevic J, Bojic M, Popovic Z, Keserovic N, Pesic M. Long-term follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones: initial results. Heart. 1996;75:596-601.
119. Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller M, Schultheiss HP. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793-2798.